Mantle Cell Lymphoma (MCL) Active Not Recruiting Phase 2 Trials for Lenalidomide (DB00480)

Also known as: Lymphoma, Mantle-Cell / Mantle Cell Lymphoma / Mantle-Cell Lymphoma / Lymphoma, Mantle- Cell / Lymphoma, Mantle Cell / Mantle-Cell Lymphomas / B cell lymphoma / Centrocytic lymphoma / Mantle cell lymphoma NOS / Mantle cell lymphomas

IndicationStatusPhase
DBCOND0071979 (Mantle Cell Lymphoma (MCL))Active Not Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00875667A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL)Treatment
NCT00783367Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell LymphomasTreatment
NCT02633137Sequential Chemotherapy and Lenalidomide Followed by Rituximab and Lenalidomide Maintenance for Untreated Mantle Cell LymphomaTreatment
NCT01472562Lenalidomide Plus Rituxan for Untreated Mantle Cell LymphomaTreatment